Ticagrelor monotherapy after PCI poses no extra revascularization risk vs. continued DAPT
Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported. The TWILIGHT trial, for which the main results were presented at TCT 2019, evaluated the efficacy and safety of ticagrelor plus aspirin compared with ticagrelor alone for bleeding and ischemic